The Broadening Application of Chemodenervation in X-Linked Dystonia-Parkinsonism (Part I): Muscle Afferent Block Versus Botulinum Toxin-A in Cervical and Limb Dystonias

REFERENCES

• Abbruzzese, G., Marchese, R., Buccolieri, A., Gasparetto, B., & Trompetto, C. (2001). Abnormalities of sensorimotor integration in dystonia. A transcranial magnetic stimulation study. Brain, 124, 537–545.
   PubMed Web of Science ®Google Scholar
• Albanese, A., Asmus, F., Bhatia, K. P., Elia, A. E., Elibol, B., Filippini, G., (2010). EFNS guidelines on diagnosis and treatment of primary dystonias. European Journal of Neurology. doi: 10.1111/j.1468-1331.2010.03042.x.
   Web of Science ®Google Scholar
• Brans, J. W., Lindeboom, R., Snoek, J. W., Zwarts, M. J., van Weerden, T. W., Brunt, E. R., (1996). Botulinum toxin versus trihexyphenidyl in cervical dystonia: A prospective, randomized, double-blind controlled trial. Neurology, 46, 1066–1072.
   PubMed Web of Science ®Google Scholar
• Comella, C. I., Tanner, C. M., DeFoor-Hill, L., & Smith, C. (1992). Dysphagia after botulinum toxin injections for spasmodic torticiollis. Clinical and radiologic findings. Neurology, 42, 1307–1310.
   PubMed Web of Science ®Google Scholar
• Consky, E. S., Basinski, A., Belle, L., Ranawaya, R., & Lang, A. E. (1990). The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): Assessment of validity and inter-rater reliability. Neurology, 40(Suppl. 1), 445.
   Google Scholar
• Costa, J., Espírito-Santo, C. C., Borges, A. A., Ferreira, J., Coelho, M. M., Moore, P., (2005a). Botulinum toxin type A therapy for cervicaldystonia. Cochrane Database of Systematic Reviews, Issue 1, Art. no.: CD003633. doi: 10.1002/14651858.CD003633.pub2.
   Web of Science ®Google Scholar
• Costa, J., Espírito-Santo, C. C., Borges, A. A., Moore, P., Ferreira, J., Coelho, M. M., (2005b). Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database of Systematic Reviews, Issue 1, Art. no.: CD004312. doi: 10.1002/14651858.CD004312.pub2.
   Web of Science ®Google Scholar
• Curra, A., Trompetto, C., Abbruzzese, G., & Berardelli, A. (2004). Central effects of botulinum toxin A. Evidence and supposition. Movement Disorders, 19(Suppl. 8), S60–S64.
   PubMed Web of Science ®Google Scholar
• Delnooz, C., Horstink, M., Tijssen, M., & van de Warrenburg, B. (2009). Paramedical treatment in primary dystonia: A systematic review. Movement Disorders, 4(15), 2187–2198.
   Google Scholar
• Evidente, V. G., Nolte, D., Niemann, S., Advincula, J., Mayo, M. C., Natividad, F. F., (2004). Phenotypic and molecular analyses of X-linked dystonia-Parkinsonism (“lubag”) in women. Archives of Neurology, 61, 1956–1959.
   PubMedGoogle Scholar
• Garner, C. G., Straube, A., Witt, T. N., & Oertel, W. H. (1993). Time course of distant effects of local injections of botulinum toxin. Movement Disorders, 8, 33–37.
   PubMed Web of Science ®Google Scholar
• Gelb, D. J., Yoshimura, D. M., Olney, R. K., Lowenstein, D. H., & Aminoff, M. J. (1991). Change in the pattern of muscle activity following botulinum toxin injections for torticollis. Annals of Neurology, 29, 370–376.
   PubMed Web of Science ®Google Scholar
• Gilio, F., Curra, A., Lorenzano, C., Modugno, A., Mangredi, M., & Berardelli, A. (2000). Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Annals of Neurology, 48, 20–26.
   PubMed Web of Science ®Google Scholar
• Horn, S., & Comella, C. L. (2004). Pharmacologic treatment of generalized dystonia. In M. F. Brin, C. L. Comella, & J. Jankovic (eds.), Dystonia: Etiology, Clinical Features, and Treatment. Philadelphia, PA: Lippincott, Williams & Wilkins, 71–77.
   Google Scholar
• Kaji, R. (2002). Muscle afferent block for dystonia: Implications for the physiological mechanism of action of botulinum toxin. In M. F. Brin, J. Jankovic, & M. Hallett (eds.), Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia, PA: Lippincott, Williams & Wilkins, 455–458.
   Google Scholar
• Kaji, R., Rothwell, J. C., Katayama, M., Ikeda, T., Kubori, T., & Kohara, N. (1995). Tonic vibration reflex and muscle afferent block in writer's cramp. Annals of Neurology, 38, 155–162.
   PubMed Web of Science ®Google Scholar
• Kanovsky, P., Streitova, H., Dufek, J., & Rektor, I. (1998). Change in lateralization of the P22/N30 cortical component of median nerve somatosensory evoked potentials in patients after successful treatment with botulinum toxin A. Movement Disorders, 13, 101–112.
   PubMed Web of Science ®Google Scholar
• Kim, D., Oh, B., & Paik, N. (2006). Central effect of botulinum toxin type A in humans. International Journal of Neuroscience, 116, 667–680.
   PubMed Web of Science ®Google Scholar
• Kupke, K. G., Lee, L. V., Viterbo, G. H., Arancillo, J., Donlon, T., & Müller, U. (1990). X-linked recessive torsion dystonia in the Philippines. American Journal of Medical Genetics, 36, 237–242.
   PubMed Web of Science ®Google Scholar
• Lee, L. V., Kupke, K. G., Caballar-Gonzaga, F., Hebron-Ortiz, M., & Muller, U. (1991). The phenotype of the X-linked dystonia-parkinsonism syndrome. An assessment of 42 cases in the Philippines. Medicine (Baltimore), 70(3), 179–187.
   PubMed Web of Science ®Google Scholar
• Lee, L. V., Maranon, E., Demaisip, C., Peralta, O., Borres-Icasiano, R., Arancillo, J., (2002). The natural history of sex-linked recessive dystonia Parkinsonism of Panay, Philippines (XDP). Parkinsonism & Related Disorders, 9, 29–38.
   PubMed Web of Science ®Google Scholar
• Lee, L. V., Munoz, E. L., Tan, K. T., & Reyes, M. T. (2001). Sex linked recessive dystonia parkinsonism of Panay, Philippines (XDP). Molecular Pathology, 54(6), 362–368.
   PubMedGoogle Scholar
• Lukban, M. B., Rosales, R. L., & Dressler, D. (2009). Effectiveness of botulinum toxin-A for upper and lower limb spasticity in children with cerebral palsy: A summary of evidence. Journal of Neural Transmission, 116, 319–331.
   PubMed Web of Science ®Google Scholar
• Massey, J. M. (2002). Electromyography-giuded chemodenervation with phenol in cervical dystonia (Spasmodic torticollis). In M. F. Brin, J. Jankovic, & M. Hallett (eds.), Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia, PA: Lippincott, Williams & Wilkins, 459–462.
   Google Scholar
• Muller, U., Herzfeld, T., & Nolte, D. (2007). The TAF1/DYT3 multiple transcript system in X-linked dystonia-parkinsonism. American Journal of Human Genetics, 81, 415–417.
   PubMed Web of Science ®Google Scholar
• Murase, N., Kaji, R., Shimazu, H., Katayama-Hirota, M., Ikeda, A., Kohara, N., (2000). Abnormal premovement gating of somatosensory input in writer's cramp. Brain, 123, 1813–1829.
   PubMed Web of Science ®Google Scholar
• Naumann, M., & Jankovic, J. (2004). Safety of botulinum toxin type A: A systematic review and meta-analysis. Current Medical Research and Opinion, 20, 981–990.
   PubMed Web of Science ®Google Scholar
• Novak, I., Campbell, L., Boyce, M., & Fung, V. S. C. (2010). Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: International consensus statement. European Journal of Neurology, 17(Suppl. 2), S94–S108.
   PubMedGoogle Scholar
• Olney, R. K., Aminoff, M. J., Gelb, D. J., & Lowenstein, D. H. (1988). Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology, 38, 1780–1783.
   PubMed Web of Science ®Google Scholar
• Pohl, C., Happe, J., & Klockgether, T. (2002). Cooling improves the writing performance of patient's with writer's cramp. Movement Disorders, 17, 1341–1344.
   PubMed Web of Science ®Google Scholar
• Rosales, R. L., & Chua-Yap, A. (2008). Evidence-based systematic review on the efficacy and safety of botulinum toxin therapy in post-stroke spasticity. Journal of Neural Transmission, 115, 617–623.
   PubMed Web of Science ®Google Scholar
• Rosales, R. L., & Dressler, D. (2010). On muscle spindles, dystonia and botulinum toxin. European Journal of Neurology (Suppl. 1), S71–S80.
   Google Scholar
• Rosales, R. L., & Kong, H. K. (2009). For the Asian Botulinum toxin study group. The Asian botulinum toxin-A (Dysport) clinical trial designed for early post-stroke spasticity (ABCDE-S trial) [abstract]. Movement Disorders, 24, S455.
   PubMed Web of Science ®Google Scholar
• Rosales, R. L., Arimura, K., Gamez, G., & Osame, M. (1995). X-linked dystonia-Parkinsonism: Botulinum toxin therapy and stimulation single-fiber electromyography. Electroencephalography & Clinical Neurophysiology, Section of Electromyography and Motor Control, 97(4), S234–S235.
   Google Scholar
• Rosales, R. L., Arimura, K., Takenaga, S., & Osame, M. (1996). Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle & Nerve, 19, 488–496.
   PubMed Web of Science ®Google Scholar
• Rosales, R. L., Bigalke, H., & Dressler, D. (2006). Pharmacology of botulinum toxin: Differences between type A preparations. European Journal of Neurology, 13(Suppl. 1), 2–10.
   PubMed Web of Science ®Google Scholar
• Rosales, R. L., Delgado, M., & Malicdan, M. (2004). Botulinum toxin A and muscle afferent block in X-linked dystonia-Parkinsonism of Panay. Movement Disorders, 19(Suppl. 9), S103–S104.
   Google Scholar
• Rosales, R. L., Delgado, M. S., & Rosales, M. E. (2002). Spasticity, X-linked dystonia, Parkinsonism and botulinum toxin A: The local scenario. In L. Battistin, M. Dam, & P. Tonin (eds.), Proceedings of the 3rd World Congress of Neurological Rehabilitation. (Venice) Italy: Monduzzi Editore, 121–126.
   Google Scholar
• Senkarova, Z., Hlustik, P., Otruba, P., Herzig, R., & Kanovsky, P. (2009). Modulation of cortical activity in patients suffering from upper arm spasticity following stroke and treated with botulinum toxin A: An fMRI study. Journal of Neuroimaging, 20, 9–15.
   PubMed Web of Science ®Google Scholar
• Susatia, F., Rosales, R. L., Diaz, J. B., & Gumangan, M. C. (2008). Comparison on morphologic changes on nerve terminals, extrafusal and intrafusal muscles following botulinum toxin-A versus botulinum toxin-B injections in experimental rats [abstract]. Neurorehabilitation & Neural Repair, 22, 203.
   Google Scholar
• Tamiya, G., Makino, S., & Kaji, R. (2007). TAF1 as the most plausible disease gene for XDP/DYT3. American Journal of Human Genetics, 81, 417–418.
   Web of Science ®Google Scholar
• Teleg, R., Dantes, M., Peralta, O., Icasiano, R., & Lee, L. V. (2005). Muscle afferent block in the treatment of X-linked dystonia-Parkinsonism (XDP). Acta Medica Philippina, 39, 28–35.
   Google Scholar
• Trompetto, C., Abbruzzese, G., Suppa, A., & Berardelli, A. (2009). Effects of botulinum toxin on central nervous system function. In J. Jankovic, A. Albanese, M. Z. Atassi, J. O. Dolly, M. Hallett, & N. H. Mayer (eds.), Botulinum toxin. Therapeutic Clinical Practice and Science. Philadelphia, PA: Saunders Elsevier, 85–91.
   Google Scholar
• Trompetto, C., Curra, A., Buccolieri, A., Suppa, A., Abbruzzese, G., & Berardelli, A. (2006). Botulinum toxin changes intrafusal feedback in dystonia: A study with the tonic vibration reflex. Movement Disorders, 21, 777–778.
   PubMed Web of Science ®Google Scholar
• Truong, D., Brodsky, M., Lew, M., Brashear, A., Jankovice, J., Molho E., Orlovag, O., & Timerbaevah, S. On behalf of the Global Dysport Cervical Dystonia Study Group. (2010). Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism and Related Disorders, 16(5), 316–323.
   PubMed Web of Science ®Google Scholar
• Valls-Sole, J., Tolosa, E. S., & Riber, G. (1991). Neurophysiological observations on the effects of botulinum toxin treatment in patients with dystonic blepharospasm. Journal of Neurology, Neurosurgery & Psychiatry, 54, 310–313.
   PubMed Web of Science ®Google Scholar
• Waters, C. H., Takahashi, H., Wilhelmsen, K. C., Shubin, R., Snow, B. J., Nygaard, T. G., (1993). Phenotypic expression of X-linked dystonia-Parkinsonism (Lubag) in two women. Neurology, 43, 1555–1558.
   PubMed Web of Science ®Google Scholar